Everett, WA – May 26, 2011 – SNBL USA, one of the nation’s leading preclinical testing companies, today announced the appointment of Stewart Jacobson, DVM, DACVP as the Director of Pathology Services. Dr. Jacobson will direct the anatomic and clinical pathology laboratory teams and manage the operation, leadership, direction, and administration of SNBL USA’s anatomic and clinical pathology laboratory teams.
“Dr. Jacobson has the proven leadership, personal energy, and expertise to drive our pathology services department,” said Dr. Thomas Beck, SNBL USA president and COO. “His industry experience and strong technical management skills will be of significant value and we are extremely pleased to welcome him to SNBL USA.”
Dr. Jacobson’s experience in the drug development industry include: acting as a Peer Review and Study Pathologist for animal studies, including both toxicology and medical device studies; management of technical staff, including operational, scientific and regulatory compliance; and developing strategies for nonclinical development programs.
Prior to joining SNBL USA, Dr. Jacobson has held various positions, including Chief Operating Officer at CVPath Institute; Senior Division Director, at Charles River Laboratories, Pathology Associates; Director, Technical Operations and Division Director, Medical Devices, at Charles River Laboratories, Pathology Associates, and Study Pathologist at Covance Laboratories. He holds a BS in Engineering/Computer Science from the University of Illinois, Urbana, a DVM from Tufts University, and completed his residency in Anatomic Veterinary Pathology at the University of Connecticut. As a board-certified diplomate by the American College of Veterinary Pathology, Dr. Jacobson provides SNBL USA a very high level of expertise and experience that will significantly benefit SNBL USA and SNBL USA clients.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging preclinical through clinical services.
